Mifepristone was the first antiprogestogen to be developed for clinical use. it is not only a progesterone receptor antagonist, but also acts as a glucocorticoid receptor antagonist. The fundamental importance of progesterone for human conception and throughout pregnancy has meant that mifepristone has been used in other countries for emergency contraception and medical abortion in the first and second trimester of pregnancy. it has also been used to manage fetal death in utero in the third trimester of pregnancy. There are other potential uses based on its mechanism of action, such as reducing the bleeding associated with uterine fibroids.
introduction
Most health professionals will be familiar with the antioestrogens, clomiphene citrate and tamoxifen. these drugs have been used for years for conditions as diverse as infertility and breast cancer respectively. It was not until 1983 that a drug with antiprogestogenic activity was developed. 1 Mifepristone was the first drug to compete with progesterone at its receptor.
pharmacology the progesterone receptor is one of several proteins synthesised by the action of oestradiol on the endometrium. this receptor is a dimer of two distinct proteins and binds progesterone which is a planar steroid. By contrast, mifepristone is a non-planar molecule. this bent, rigid, molecular structure seems important for antisteroid compounds.
Mifepristone binds to the progesterone receptor five times more avidly than progesterone. It also binds with the glucocorticoid receptor three times more strongly than dexamethasone. By contrast, mifepristone binds to the androgen receptor with only one quarter of the affinity of testosterone and has essentially no binding to the mineralocorticoid receptor or oestradiol receptors.
Approximately 85% of mifepristone is absorbed after oral administration. It has a long elimination half-life. 
Medical abortion

Medical and surgical abortion compared
In most studies of women undergoing first trimester abortion, approximately 25% choose medical abortion, a further 25% prefer surgery and the remainder have no strong preference for either technique. 6,7 the requirements for a medical abortion differ in many respects from those of a surgical abortion.
Some patients strongly prefer that friends or family can be present during medical abortion, and patients are not required to fast. Patients in the WHo studies commented on a more friendly approach with medical abortion, which they considered psychologically beneficial at a time when anxiety levels were increased. 
other uses
As mifepristone has antiprogestogenic activity, it has been studied in situations where its action on receptors may alter the course of the conditions.
Intrauterine fetal death
Progesterone is critical for establishing and maintaining pregnancy. the first WHo study in Australia used mifepristone to manage fetal death in late pregnancy. In these cases, the baby has died, but the placenta has not and it continues to synthesise progesterone for some weeks. this prevents labour and continues the pregnancy in very difficult emotional circumstances for the woman carrying a dead baby. For women with an unexplained fetal death in utero, and who have an unripe cervix, mifepristone typically induces delivery within 72 hours.
Contraception
Mifepristone has been used as an emergency contraceptive. In randomised controlled studies, it appears as effective as other regimens, such as those using levonorgestrel. In WHo studies of emergency contraception within seven days of unprotected intercourse, mifepristone was effective at doses of 600 mg, 50 mg and even 10 mg. 11 this is important in low income countries with limited pharmaceutical resources. 
Uterine fibroids
Cushing's syndrome
As mifepristone is a glucocorticoid receptor antagonist, it has been studied in Cushing's syndrome. the first patient to be treated received mifepristone doses of up to 1500 mg daily for nine weeks.
No adverse effects were observed. Some patients with Cushing's syndrome have been treated with mifepristone for up to 10 years. there has recently been a change in legislation in Australia. 18 A sponsor may emerge for mifepristone in the near future.
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